FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in ...

If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan.

Milestone Pharmaceuticals (NASDAQ:MIST) executives highlighted the company’s transition to commercialization during a ...

Milestone Pharmaceuticals Inc. MIST shares are tumbling on Friday after the company revealed a minor pushback in European approval for its lead drug. • Milestone Pharmaceuticals stock is taking a hit ...

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated ...

Credit: Milestone Pharmaceuticals. Each nasal spray device delivers 2 sprays containing a total of etripamil 70mg. The intranasal therapy consists of a novel calcium channel blocker and is designed to ...

PSVT involves episodes of a faster-than-normal heart rate, often with symptoms resembling anxiety attacks, and while uncomfortable, it’s typically not life threatening. Diagnosis of PSVT typically ...

Cardamyst (etripamil) is a nose spray that helps treat sudden episodes of fast heartbeats, known as paroxysmal supraventricular tachycardia (PSVT). PSVT is a type of abnormal heart rhythm where your ...

Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response ...

Even though PSVT doesn’t seem to lead to serious long-term health issues, you should still talk to your doctor. These symptoms could be signs of another health problem. Cells in the upper chambers of ...